within Pharmacolibrary.Drugs.N_NervousSystem.N07X_OtherNervousSystemDrugs.N07XX12_Patisiran;

model Patisiran
  extends Pharmacolibrary.Drugs.ATC.N.N07XX12;

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>Patisiran</td></tr><tr><td>ATC code:</td><td>N07XX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Patisiran is an RNA interference (RNAi) therapeutic agent approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It works by silencing the transthyretin (TTR) gene, thereby reducing the production of mutant and wild-type TTR protein which forms amyloid deposits.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with hereditary transthyretin-mediated amyloidosis; values pertain to patisiran lipid nanoparticle (LNP) formulation after intravenous administration.</p><h4>References</h4><ol><li><p>Suhr, OB, et al., &amp; Adams, D (2015). Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. <i>Orphanet journal of rare diseases</i> 10 109â€“None. DOI:<a href=\"https://doi.org/10.1186/s13023-015-0326-6\">10.1186/s13023-015-0326-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26338094/\">https://pubmed.ncbi.nlm.nih.gov/26338094</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Patisiran;
